New genetic test may predict prostate cancer drug response before surgery
NCT ID NCT07617272
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a new genetic test (called PCAI ImmunoScore) can predict how well men with high-risk prostate cancer will respond to the drug darolutamide before surgery. About 100 participants will take darolutamide for 3-4 months, then have their prostate removed. Researchers will check if the genetic test matches the actual tumor shrinkage seen after surgery. The goal is to better identify who benefits from this treatment approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karolinska University Hospital
RECRUITINGStockholm, SE-17176, Sweden
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A sharper eye on prostate cancer: could new imaging spare healthy tissue?
- Can a new drug combo tame resistant prostate cancer?
- Virtual cooking classes aim to boost health for hispanic prostate cancer survivors and their families
- Prostate Surgery's hidden toll: study probes lasting impact on Men's lives
- Which gas pump causes less pain during robotic prostate surgery? a Head-to-Head trial
- Nerve-Sparing radiation may help men keep sexual function after prostate cancer treatment